This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), is focused on understanding and overcoming resistance of breast cancer brain metastases to RET inhibitor therapy. The 2-year, $802,230 award to the University of Texas Health Science Center at Houston will investigate the role of the TGLI1 oncogene in mediating resistance to RET inhibition, and determine if dual targeting of RET and TGLI1 can synergistically inhibit breast cancer brain metastases. The research aims to identify actionable drug targets and develop novel combination therapies for this deadly condition, which has limited treatment options and extremely poor prognoses. The project will leverage the institution's expertise in areas such as cancer biology, drug discovery, and preclinical models to advance scientific understanding and potentially transform the treatment landscape for breast cancer brain metastases.
Generated 3/25/25, 3:40 AM